UK Markets open in 1 hr 36 mins

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
17.50-0.20 (-1.13%)
At close: 09:07AM CET
Full screen
Previous close17.70
Open17.50
Bid0.00 x N/A
Ask0.00 x N/A
Day's range17.50 - 17.50
52-week range16.90 - 27.30
Volume100
Avg. volume69
Market cap148.75M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.17
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est36.50
  • EQS Group

    APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed new CFO

    DGAP-News: APONTIS PHARMA AG / Key word(s): Personnel16.12.2021 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed CFOMonheim am Rhein, 16 December 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, strengthens its management for future growth and appoints Thomas Zimmermann as Chief Financial Of

  • EQS Group

    APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch/Alliance14.12.2021 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights Continued expansion of the mid-term Single Pill portfolio for the treatment of hypertension APONTIS PHARMA for the first time owns all Europe-wide rights (IP - Intellectual Property) to the preparation, medicat

  • EQS Group

    APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 - Revenue forecast increased

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement/9 Month figures18.11.2021 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 - Revenue forecast increased Single Pills revenues +80% to EUR 21.8 million as key growth driver Total revenues grow faster than pharmaceutical sector by 37% to EUR 36.7 million EBITDA (adjusted) increases significantly by EUR